Back to results
US 9,849,124 B2Granted
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AssigneePurdue Pharma L.P.
InventorsMichele Hummel, Donald J. Kyle, Garth Whiteside
Life of this patent
Estimating the term…
Abstract
Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
Claims16
A method of preventing or treating an opioid-induced adverse pharmacodynamic response comprising:
- concurrently administering to a patient in need thereof an effective amount of an opioid agonist selected from the group consisting of oxycodone, morphine, codeine, oxymorphone, fentanyl, hydrocodone, hydromorphone, tramadol, and a pharmaceutically acceptable salt thereof to provide an analgesic effect and an effective amount of buprenorphine to prevent or treat an adverse pharmacodynamic response induced by the administration of the opioid agonist,
- wherein the buprenorphine is sub-analgetic and does not affect the analgesic effect of the opioid agonist.
A pharmaceutical unit dosage form comprising:
- (i) an effective amount of an opioid agonist selected from the group consisting of oxycodone, morphine, codeine, oxymorphone, fentanyl, hydrocodone, hydromorphone, tramadol and a pharmaceutically acceptable salt thereof to provide an analgesic effect, and
- (ii) an effective amount of buprenorphine to prevent or treat an adverse pharmacodynamic response induced by the opioid,
- wherein the buprenorphine is sub-analgetic and does not affect the analgesic effect of the opioid agonist.
A kit comprising:
- (i) a unit dose of an effective amount of an opioid agonist selected from the group consisting of oxycodone, morphine, codeine, oxymorphone, fentanyl, hydrocodone, hydromorphone, tramadol and a pharmaceutically acceptable salt thereof to provide an analgesic effect, and
- (ii) a unit dose of an effective amount of buprenorphine to prevent or treat an opioid-induced adverse pharmacodynamic response induced by the opioid agonist, wherein the buprenorphine is sub-analgetic and does not affect the analgesic effect of the opioid agonist.
Dependencies are inferred from the claim text.